semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Both gender patients aged over 18 years Diagnosis of chronic heart failure (identified by the use of Framingham criteria) for ≥ 6 months New York Heart Association functional class II and III Left ventricular ejection fraction ≤ 45% Regular attendance in an outpatient Heart Failure Clinic Adequate therapeutic drug for heart failure syndrome based on beta-adrenergic blocker, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and mineralocorticoid receptor blocker Evidence of iron deficiency in biochemical analyses: ferritin values < 100 ng/dL or between 100 ng/dL and 300 ng/dL, with transferrin saturation < 20% Hemoglobin value between 9,0 g/dL Provide written informed consent  Recent device implant (in the last 3 months) or perspective of device implantation (conventional or multisite pacing) in the next 6 months Known active infection, inflammatory disease or C-reactive protein > 20 mg/dL Immunosuppressive therapy In use of erythropoietin and/or current treatment with oral or intravenous iron Clinically bleeding or blood transfusion in previous 3 months Renal failure on dialysis Hemoglobinopathies, hemochromatosis or active malignancy Unstable angina pectoris or clinically significant uncorrected valvular disease, except mitral and tricuspid regurgitation secondary to ventricular dilatation Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack within the last 3 months Uncontrolled arterial hypertension
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diabetes Mellitus, Type 2 Obesity BMI > 35 kg/m2 Diabetes Mellitus, type 2  Diabetes Mellitus, type 1 Chronic obstructive lung disease Heart failure or other cardiac disease Chronic inflammatory diseases Hepatitis or HIV Anemia Abnormal kidney or liver function Metabolic disease Prescription of prednisolone as pill or injection in the study period or 3 months prior to study start Alcoholism or abuse of other substances
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Type 1 Diabetes Mellitus Diabetes Men and women between the ages of 18 and 60 years old, inclusive, at the time of screening Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception Male subjects must be willing to use clinically acceptable method of contraception during the entire study Body mass index between 18.5 and 26.9 kg/m2, inclusive, at screening Diagnosed with Type 1 diabetes for greater than 2 years, based on clinical history or as defined by the current American Diabetes Association (ADA) criteria HbA1c ≥6.0 % but <9.0 % at screening Fasting C-peptide <0.2 ng/mL Current use of insulin pump and willing to use continuous glucose monitoring (CGM) system (e.g. DexCom) throughout the entire study ALT and/or AST within <1.5x ULN at screening Serum amylase and lipase within normal limits at screening  History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion Significant organ system dysfunction (e.g., clinically significant pulmonary or cardiovascular disease, anemia [Hemoglobin <10.0 g/dL], and renal dysfunction [eGFR <90 ml/1.73M2/min]) Any severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or medical facility in the past 6 months Current or recent (within 1 month of screening) use of diabetes medications other than insulin Use of steroids and/or other prescribed or over-the-counter medications that are known to affect the outcome measures in this study or known to influence glucose metabolism Smokes tobacco Known sensitivity to mammalian-derived drug preparations, recombinant protein-based drugs or to humanized or human antibodies History of illegal drug use or alcohol abuse within the last 6 months or a positive drug urine test result at screening History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia History of pheochromocytoma, or family history of familial pheochromocytoma
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chest Pain Dyspnea ED patients with a chief complaint of chest pain or shortness of breath Cardiac Ultrasound ordered by provider as part of diagnostic workup  All providers have already reviewed the ultrasound images (unable to obtained pre- ultrasound assessment) Age < 18 Known to be pregnant
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes The subject has type 1 diabetes as defined by WHO The subject is 18 years of age or older The subject will have been on an insulin pump for at least 6 months with good knowledge of insulin self-adjustment including carbohydrate counting The subject is treated with one of the rapid acting insulin analogues (Insulin Aspart, Insulin Lispro or Insulin Glulisine) HbA1c <7.5% (58mmol/mmol) based on analysis from central laboratory or equivalent The subject is willing to perform regular finger-prick blood glucose monitoring, with at least 6 measurements per day The subject is willing to wear closed-loop system at home and at work place The subject is willing to follow study specific instructions The subject is willing to upload pump and CGM data at regular intervals Female subjects of child bearing age should be on effective contraception and must have a negative urine-HCG pregnancy test at screening  Non-type 1 diabetes mellitus Any other physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results Current treatment with drugs known to have significant interference with glucose metabolism, such as systemic corticosteroids, as judged by the investigator Known or suspected allergy against insulin Subjects with clinically significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator Significantly reduced hypoglycaemia awareness as judged by the investigator More than one episode of severe hypoglycaemia as defined by American Diabetes Association in preceding 6 months (Severe hypoglycaemia is defined as an event requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions) Random C-peptide > 100pmol/l with concomitant plasma glucose >4 mM(72 mg/dl) Total daily insulin dose > 2 IU/kg/day Subject is pregnant or breast feeding or planning pregnancy in near future (within next 3 months) Severe visual impairment
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diabetes Mellitus With Periodontal Disease Patients with diabetes mellitus type II (at least 3 months before diagnosis, and A fasting blood sugar level of more than 125 mg/dl) and has periodontal disease is a chronic moderate (has a clinical attachment level of 3-4 mm) peritonitis Minimum of 16 natural teeth, and no periodontal treatment in the prior 6 months Had a glycated α hemoglobin (HbA1c) value between 7 percent at screening Had reported no changes in diabetes medications within the last 3 months were in the care of a physician for their diabetes  Pregnancy or lactation History of allergy to drugs used in the study Smoking Diabetes-related emergency within 30 days ago Use of nonsteroidal anti-inflammatory drugs Or taking low dose daily aspirin (75-325 mg)\ Use of immunosuppressive medications; antibiotic use Dialysis Risk of bleeding complications The type of disease periodontal (Aggressive)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Skeletal Dysplasia All included individuals must provide informed consent 2. Patients identified to have a skeletal dysplasia 3. All ethnic backgrounds are acceptable 4. Disease must be genetic with no evident environmental cause. 5. Evidence of Mendelian Transmission determined by fulfilling one of the following 1. Multiple affected family members (at least first-degree relative with disease) 2. History of consanguinity 3. Severe disease in newborn in the absence of family history 4. Syndromic disease in single individuals 5. Congenital abnormality affecting major organ system(s) 6. Mendelianized extremes of common disease (e.g. bilateral developmental dysplasia of the hip) 6. All ages will be included 7. Rare diseases or rare forms of known diseases 8. Unaffected family members or relatives of the individual with the primary syndrome  Individuals who do not consent will not be included 2. Individuals for which a molecular diagnosis has already been established by alternative method (e.g. karyotype or known gene mutation) 3. Diseases for which an environmental factor is most likely the cause (e.g. Traumatic bone injury or Rickets) 4. Diseases of which late age of onset rule out Mendelian transmission 5. Common Diseases for which late age of onset rule out Mendelian transmission (e.g.Osteoporosis)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dilated Cardiomyopathy Patient diagnosed with dilated cardiomyopathy (DCM) with an initial HFrEF < 40 % at presentation. 2. DCM with recovered LV function to > or = to 50% documented on 2 ECHO examinations, with the most recent ECHO examination within 1 year of enrolment. 3. Time from initial diagnosis of DCM more or equal to 24 month. 4. Last hospitalization for decompensated HF > 1year  Ischemic cardiomyopathy 2. Other structural pathology such as: Hypertrophic cardiomyopathy, Valvular cardiomyopathy or congenital heart disease. 3. Last hospitalization for decompensated HF < 1year ago. 4. Previous sustained ventricle tachycardia or ventricle fibrillation (VF) arrest
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 34.0-68.0,  Diabetes Mellitus, Type 2 The patients were diagnosed with T2DM according to the guidelines of the American Diabetes Association; 2. No smoking history, pulmonary disease nor pulmonary infection within a fortnight; 3. Did not have hepatopathy, nephropathy, and gastrointestinal disease; and 4. Likely to have good compliance and able to visit our hospital for periodic assessments  T1DM, gestation and lactation; 2. Renal inadequacy, a serum creatinine >132 µmol/L (male), or a serum creatinine >123 µmol/L (female); 3. hypohepatia, the liver enzyme was two times higher than normal; 4. Intensive care with insulin treatment; 5. The patients combinated with DR and hypertension (antihypertensive drugs were used); 6. Patients with other eye conditions that could affect the blood flow, such as high degree myopia, maculopathy of any origin, glaucoma, and those with a history of laser treatment or introacular surgery; 7. New York Heart Association class III or IV heart failure, a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months; 8) Cholesterol-lowering drugs can not control the blood-fat (TC > 250 mg/dl, HDL-C < 30 mg/dL, LDL-C > 170 mg/dl, TG > 200 mg/dl) adequately; and 9) Use of systemically injected glucocorticoids within 3 months prior to our study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 16.0-24.0,  Type 1 Diabetes The subject is between 16 and 24 years of age (inclusive) The subject has type 1 diabetes, as defined by WHO for at least 6 months or is confirmed C-peptide negative The subject will have been on insulin pump or MDI therapy for at least 6 months Body Mass Index (BMI) < 30 kg/m2 HbA1c ≤ 12 % based on analysis from central laboratory  Non-type 1 diabetes mellitus including those secondary to chronic disease Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and MAO inhibitors Experienced recurrent severe hypoglycaemic unawareness (as judged by the investigator) Known or suspected allergy against insulin Subjects with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator Total daily insulin dose = 1.4 IU/kg Pregnancy or intention of becoming pregnant, breast-feeding or judged to be using inadequate contraceptive methods. Adequate contraceptive methods are sterilisation, intrauterine device (IUD), oral contraceptives or consistent use of barrier methods Gastroparesis Symptomatic hypoglycaemia within 48h prior to study nights
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Dyspnea healthy volunteers  pregnancy ongoing pain respiratory disease high levels of depression, panic disorder, or other significant mental health problems not fluent in french
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 1 Male or female aged >18 years, inclusive Clinical history compatible with T1D with onset of disease at < 40 years of age, insulin dependence for ≥ 5 years at the time of enrolment C-peptide concentrations under the threshold of preserved beta cell function: fasting C peptide <0.23 ng/ml Detectable fasting proinsulin concentrations (>0.5 pmol/l) Ability to provide written informed consent Mentally stable and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations  Body mass index (BMI) >30 kg/m2 or patient with body weight ≤40kg Insulin requirement >1.0 IU/kg/day or <10 U/day HbA1c >11% (normal value: 3.5-6.0%) at the time of enrolment estimated glomerular filtration rate <60 mL/min/1.73m2 calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease [MDRD] study estimation formula) Presence or history of macroalbuminuria (>300mg/g creatinine) For female subjects: positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation of treatment Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB) as determined by a positive skin test or clinical presentation, or under treatment for suspected TB Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin Lymphopenia (<1,000/μL), neutropenia (<1,500/μL), or thrombocytopenia (platelets <100,000/μL) Severe unremitting diarrhea, vomiting or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications